State Street Corp Has $32.87 Million Position in Harrow, Inc. (NASDAQ:HROW)

State Street Corp grew its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 2.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 730,973 shares of the company's stock after acquiring an additional 15,554 shares during the period. State Street Corp owned about 2.06% of Harrow worth $32,865,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in shares of Harrow by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company's stock valued at $1,843,000 after purchasing an additional 12,580 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock valued at $44,000 after buying an additional 2,048 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Harrow in the second quarter worth about $33,000. Drive Wealth Management LLC raised its holdings in shares of Harrow by 63.1% during the second quarter. Drive Wealth Management LLC now owns 29,551 shares of the company's stock valued at $617,000 after acquiring an additional 11,434 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Harrow by 8.2% during the second quarter. Rhumbline Advisers now owns 43,021 shares of the company's stock valued at $899,000 after acquiring an additional 3,253 shares during the period. 72.76% of the stock is owned by institutional investors.

Harrow Trading Down 0.6 %

Shares of NASDAQ:HROW opened at $34.22 on Friday. Harrow, Inc. has a 12-month low of $9.13 and a 12-month high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm has a market capitalization of $1.22 billion, a P/E ratio of -36.40 and a beta of 0.69. The firm has a fifty day moving average of $44.55 and a two-hundred day moving average of $36.65.

Analysts Set New Price Targets

Several equities analysts have weighed in on HROW shares. B. Riley lowered their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research report on Wednesday, December 4th. Lake Street Capital upped their price target on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. Finally, Craig Hallum raised their price objective on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.